Tarsus Pharmaceuticals Inc - Asset Resilience Ratio
Tarsus Pharmaceuticals Inc (TARS) has an Asset Resilience Ratio of 54.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Tarsus Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Tarsus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Tarsus Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tarsus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Tarsus Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $289.11 Million | 54.08% |
| Total Liquid Assets | $289.11 Million | 54.08% |
Asset Resilience Insights
- Very High Liquidity: Tarsus Pharmaceuticals Inc maintains exceptional liquid asset reserves at 54.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tarsus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Tarsus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Tarsus Pharmaceuticals Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Tarsus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.14% | $196.56 Million | $376.99 Million | +51.20pp |
| 2023-12-31 | 0.94% | $2.50 Million | $265.49 Million | -62.86pp |
| 2022-12-31 | 63.80% | $145.37 Million | $227.86 Million | +63.53pp |
| 2021-12-31 | 0.27% | $483.00K | $178.91 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $171.97 Million | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing T… Read more